2. Academic Validation
  3. CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity

CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity

  • Cell Stem Cell. 2024 Dec 5;31(12):1760-1776.e9. doi: 10.1016/j.stem.2024.10.007.
Chun Liu 1,  Mengcheng Shen 2,  Yanxia Liu 3,  Amit Manhas 2,  Shane Rui Zhao 2,  Mao Zhang 2,  Nadjet Belbachir 2,  Lu Ren 2,  Joe Z Zhang 2,  Arianne Caudal 2,  Masataka Nishiga 2,  Dilip Thomas 2,  Angela Zhang 4,  Huaxiao Yang 5,  Yang Zhou 2,  Mohamed Ameen 2,  Nazish Sayed 6,  June-Wha Rhee 7,  Lei S Qi 8,  Joseph C Wu 9
Affiliations

Affiliations

  • 1 Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Physiology and Cancer Center, Milwaukee, WI, USA; Department of Medicine and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: chunliu@mcw.edu.
  • 2 Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA; Department of Medicine (Division of Cardiology), Stanford, CA, USA.
  • 3 Department of Bioengineering, Stanford, CA, USA; Sarafan ChEM-H, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • 4 Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Greentstone Biosciences, Palo Alto, CA, USA.
  • 5 Department of Biomedical Engineering, University of North Texas, Denton, TX, USA.
  • 6 Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Medicine (Division of Cardiology), Stanford, CA, USA; Department of Surgery, Division of Vascular Surgery, Stanford University, Stanford, CA, USA.
  • 7 Department of Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • 8 Department of Bioengineering, Stanford, CA, USA; Sarafan ChEM-H, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: slqi@stanford.edu.
  • 9 Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA; Department of Medicine (Division of Cardiology), Stanford, CA, USA. Electronic address: joewu@stanford.edu.
PMID: 39515331 DOI: 10.1016/j.stem.2024.10.007
Abstract

Doxorubicin is limited in its therapeutic utility due to its life-threatening cardiovascular side effects. Here, we present an integrated drug discovery pipeline combining human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iCMs), CRISPR interference and activation (CRISPRi/a) bidirectional pooled screens, and a small-molecule screening to identify therapeutic targets mitigating doxorubicin-induced cardiotoxicity (DIC) without compromising its oncological effects. The screens revealed several previously unreported candidate genes contributing to DIC, including Carbonic Anhydrase 12 (CA12). Genetic inhibition of CA12 protected iCMs against DIC by improving cell survival, sarcomere structural integrity, contractile function, and calcium handling. Indisulam, a CA12 antagonist, can effectively attenuate DIC in iCMs, engineered heart tissue, and animal models. Mechanistically, doxorubicin-induced CA12 potentiated a glycolytic activation in cardiomyocytes, contributing to DIC by interfering with cellular metabolism and functions. Collectively, our study provides a roadmap for future drug discovery efforts, potentially leading to more targeted therapies with minimal off-target toxicity.

Keywords

CRISPR screen; carbonic anhydrase; cardio-oncology; cardiomyoctye; doxorubicin; glycolysis; iPSC.

Figures
Products